Randomized trial of infusion set function: Steel versus teflon

Diabetes Technology and Therapeutics

Volumn 16, Issue 1, 2014, Pages 15-19

  Patel, Parul J ^a   Benasi, Kari ^a   Ferrari, Gina ^a   Evans, Mark G ^a   Shanmugham, Satya ^a   Wilson, Darrell M ^a   Buckingham, Bruce A ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INSULIN; POLITEF; STEEL;

ADOLESCENT; ADULT; ARTICLE; CATHETER; CONTROLLED STUDY; CROSSOVER PROCEDURE; ERYTHEMA; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; MIDDLE AGED; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; BODY MASS INDEX; CATHETERIZATION; CHILD; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; EQUIPMENT DESIGN; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, INTRAVENOUS; INSULIN; MALE; MONITORING, PHYSIOLOGIC; POLYTETRAFLUOROETHYLENE; STEEL; TIME FACTORS;

EID: 84891838991     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0119     Document Type: Article

References (18)

1. Pickup JC, Sutton AJ: Severe hypoglycaemia and glycaemic control in Type 1 diabetes: Meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008;25:765-774.
2. Pickup J, Mattock M, Kerry S: Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: Meta-analysis of randomised controlled trials. BMJ 2002; 324:705.
3. Centers for Disease Control: Toxic-shock syndrome in a patient using a continuous subcutaneous insulin infusion pump - Idaho. MMWR Morb Mortal Wkly Rep 1983;32:404-406, 412.
4. Thethi TK, Rao A, Kawji H, Mallik T, Yau CL, Christians U, Fonseca V: Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complications 2010;24:73-78.
5. Højbjerre L, Skov-Jensen C, Kaastrup P, Pedersen PE, Stallknecht B: Effect of steel and Teflon infusion catheters on subcutaneous adipose tissue blood flow and infusion counter pressure in humans. Diabetes Technol Ther 2009;11: 301-306.
6. Johansson UB, Adamson U, Lins PE, Wredling R: Patient management of long-term continuous subcutaneous insulin infusion. J Adv Nurs 2005;51:112-118. (Pubitemid 40977312)
7. Renard E, Guerci B, Leguerrier AM, Boizel R: Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: Prospective, two-period, observational, multicenter study. Diabetes Technol Ther 2010;12:769-773.
8. Gibney MA, Arce CH, Byron KJ, Hirsch LJ: Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: Implications for needle length recommendations. Curr Med Res Opin 2010;26:1519-1530.
9. Lo Presti D, Ingegnosi C, Strauss K: Skin and subcutaneous thickness at injecting sites in children with diabetes: Ultrasound findings and recommendations for giving injection. Pediatr Diabetes 2012;13:525-533.
10. Mecklenburg RS, Benson EA, Benson JW Jr, Blumenstein BA, Fredlund PN, Quinn TS, Metz RJ, Nielsen RL: Long-term metabolic control with insulin pump therapy. Report of experience with 127 patients. N Engl J Med 1985;313:465-468. (Pubitemid 15015073)
11. Mecklenburg RS, Benson EA, Benson JW Jr, Fredlund PA, Quinn T, Metz RJ, Nielsen RL, Sanner CA: Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA 1984;252:3265-3269. (Pubitemid 15183965)
12. Wood JR,Moreland EC, Volkening LK, Svoren BM, Butler DA, Laffel LM: Durability of insulin pump use in pediatric patients with type 1 diabetes. Diabetes Care 2006;29:2355-2360. (Pubitemid 44912235)
13. Schober E, Rami B: Dermatological side effects and complications of continuous subcutaneous insulin infusion in preschool-age and school-age children. Pediatr Diabetes 2009; 10:198-201.
14. Conwell LS, Pope E, Artiles AM, Mohanta A, Daneman A, Daneman D: Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. J Pediatr 2008;152:622-628.
15. van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G: Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: A randomized controlled trial. Diabetes Technol Ther 2011;13:607-614.
16. Schmid V, Hohberg C, Borchert M, Forst T, Pfutzner A: Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy - trouble starts on day. J Diabetes Sci Technol 2010;4:976-982.
17. Wolpert HA, Faradji RN, Bonner-Weir S, Lipes MA: Metabolic decompensation in pump users due to lispro insulin precipitation. BMJ 2002;324:1253. (Pubitemid 34553564)
18. Roche ACCU-CHEK FlexLink Plus infusion set: Class I recall - potential for under-delivery of insulin. 2011. www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlerts forHumanMedicalProducts/ucm248784.htm (accessed September 10, 2013).